Logo for BioCardia Inc

BioCardia Investor Relations Material

Latest events

Logo for BioCardia Inc

Q1 2024

BioCardia
Logo for BioCardia

Q1 2024

14 May, 2024
Logo for BioCardia

Status Update

30 Apr, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from BioCardia Inc

Access all reports
BioCardia Inc. is a clinical-stage regenerative medicine company focused on developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. The company's leading therapeutic candidate, CardiAMP, is an autologous mononuclear cell therapy system designed for treating heart failure and chronic myocardial ischemia, alongside an allogeneic cell therapy for cardiac and pulmonary disease. BioCardia is also advancing an allogeneic cells therapeutic platform, in Phase I/II trial for ischemic heart failure treatment. Additionally, BioCardia offers the Helix biotherapeutic delivery system for precise heart muscle treatments and Morph deflectable guides and sheaths. The company is headquartered in Sunnyvale, California, and its shares are listed on the Nasdaq.